Everest Medicines Ltd. · HKEX:1952
Everest Medicines — H1 2026 Earnings Presentation
30 slides from Everest Medicines's earnings presentation, August 2026
Slide 1: Better Medicines, Better Life: 2026 Interim Result Investor Meeting
Better Medicines, Better Life 2026 Interim Result Investor Meeting August 2026
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by Everest Medicines Limited (the “Company” and together with its subsidiaries, the “Group”) solely for information purposes and does not constitute a recommendation regarding the securities of the Group or an offer to sell or issue or the solicitation
Slide 3: Agenda
Agenda 2026H1 Financial Ian Woo 1 Performance Executive Director, President and Chief Financial Officer Business Operation Rogers Luo 2 Update Executive Director, Chief Executive Officer Bill Wu 3 Corporate Strategy Chair of Board of Directors, Executive Director 4 Q&A Management Team 3 3
Slide 4: 1H 2026 Highlights: Strong Revenue Growth; Non-IFRS Profitability; Robust Cash Position
1H 2026 Highlights: Strong Revenue Growth; Non-IFRS Profitability; Robust Cash Position Revenue Adjusted Gross Profit IFRS Net Loss Cash Balance Margin1 RMB1.15 billion 73.7% RMB5.9 million RMB1.86 billion -RMB xx +157% YoY -2.7pp YoY million Narrowed YoY net loss RMB770m EVER001 upfront payment rec
Slide 5: 1H 2026 Performance: Continued Investment to Support Growth While Improving Financial Performance
1H 2026 Performance: Continued Investment to Support Growth While Improving Financial Performance Sales Expenses and Proportion R&D Expenses and Proportion General and Administrative Expenses and Proportion RMB (100 million) 70.55% 43.76% 24.84% 39.86% 22.31% 12.95% +45% +34% +31% 4.58 2.56 1.49 3.1
Slide 6: Income Statement and Cash Position
Income Statement and Cash Position RMB'000 2026H1 2025H1 Revenue 1,147,840 446,123 Cost of revenue -348,522 -146,728 Gross profit 799,318 299,395 Revenue +157% to RMB1,148m on rapid NEFECON® uptake General and administrative expenses -148,634 -110,795 post-NRDL and higher CSO service income Research
Slide 7: 2026 Year-to-Date Operational Highlights
2026 Year-to-Date Operational Highlights Commercialisation R&D BD collaboration ✓ Phase II basket trial ✓ EVER001 exclusive licensing and ✓ Revenue RMB889m; EVER001 initiated; out-licensing collaboration agreement signed in-market sales agreement signed +94% YoY ✓ In-licensed MT1013, Bejescin and ✓
Slide 8: NEFECON: Revenue Continues to Grow Rapidly as Foundational First-Line Therapy for IgAN
NEFECON®: Revenue Continues to Grow Rapidly, Reinforcing its Position as a Foundational First-Line Therapy for IgAN Expand commercial investment to sustain rapid Strengthening the body of clinical evidence to reinforce revenue growth NEFECON® as a foundational first-line therapy 33 Presentations at
Slide 9: Velsipity: Approved for Marketing; Advancing NRDL Negotiations in 2H 2026
Velsipity®: Approved for Marketing; Advancing NRDL Negotiations in 2H 2026 Deep mucosal healing with the potential to Accelerate Market Access reduce disease recurrence Approved in First prescription Approved in 51.9% mucosal healing rate: Favourable safety, with a low Chinese Mainland was issued in
Slide 10: XERAVA: Strong Clinical Demand Amid Tight Supply; Localised Manufacturing on Track
XERAVA®: Strong Clinical Demand Amid Tight Supply; Localised Manufacturing on Track to Support NRDL Negotiations Inclusion in multiple clinical guidelines Expand coverage of and expert consensus documents to core hospitals support broader clinical adoption ✓ Hospital sales volume ✓ Expand coverage i
Slide 11: CSO Services for Hasten's Mature Products: Creating Strategic Synergies
CSO Services for Hasten’s Mature Products: Creating Strategic Synergies Across Core Products and Building Full Life- Cycle Commercial Capabilities Launched in March 2026 and already contributing meaningful revenue and profit Expanding hospital coverage RMB 145m RMB 28m 10,000 15,000+ service fees pr
Slide 12: Near-Term Commercial Pipeline Outlook: 2026-2028
Near-Term Commercial Pipeline Outlook: 2026-2028 2026 2027 2028 MT1013 • Approved in February 2026 • Potential first- and best-in-class eye drop for • Bifunctional polypeptide with calcimimetic and presbyopia; constricts the pupil and improves osteogenic activity; regulates bone metabolism • First p
Slide 13: Cardamyst: China NDA Approval Expected in Q3 2026; Launch Preparations Underway
Cardamyst®: China NDA Approval Expected in Q3 2026; Commercial Launch Preparations Underway More than 12 million patients in China Patients receiving treatment Potential patients: 3~6 million for PSVT: 600,000~1.2 million have paroxysmal supraventricular tachycardia (PSVT) or atrial fibrillation wit
Slide 14: VIZZ: Positioned to Become China's First Approved Prescription Drug for Presbyopia
VIZZ®: Positioned to Become China's First Approved Prescription Drug for Presbyopia, With Consumer Appeal and Blockbuster Potential Large Presbyopia Patient Population with Significant Unmet Need ✓ Works fast and lasts: One dose of VlZZ® restores clear near vision within 30 minutes, offering up to 1
Slide 15: MT1013: A Dual-Mechanism Therapy for Secondary Hyperparathyroidism
MT1013: A Dual-Mechanism Therapy for Secondary Hyperparathyroidism (SHPT) with the Potential to Redefine Treatment SHPT represents a significant disease burden MT1013 combines calcimimetic and osteogenic benefits with best- in-class potential and large patient population in China SHPT is among the m
Slide 16: EVER001: Exclusive Licensing and Collaboration Agreement for pMN and Autoimmune Kidney Diseases
EVER001: Exclusive Licensing and Collaboration Agreement to Accelerate Global Clinical Development in pMN and Other Autoimmune Kidney Diseases A potent reversible covalent BTK inhibitor EVER001 EXCLUSIVE LICENSING AND with pipeline-in-a-product development potential COLLABORATION AGREEMENT SIGNED Re
Slide 17: DMX-200: Granted FDA and EMA Orphan Drug Designation
DMX-200: Granted FDA and EMA Orphan Drug Designation; Expected to Address the Unmet Need in FSGS in China Focal segmental glomurular sclerosis Efficacy (FSGS) • Exploratory Phase II: DMX-200 reduced proteinuria by 12% and urinary CCL2 by 25% vs placebo at Week 161 (see figure) • First Phase III inte
Slide 18: Nephrology Strategy: Expanding Beyond IgAN into Broader Glomerulonephritis and CKD
Nephrology Strategy: Expanding Beyond IgAN into Broader Glomerulonephritis, CKD and Related Complications Glomerulonephritis CKD and Related ~10 million patients Complications Beyond IgAN, includes MN, MCD, FSGS and LN >100 million patients IgAN Complications including CKD-MBD and renal anemia ~5 mi
Slide 19: Proprietary mRNA Platform: Cancer Vaccines and In Vivo CAR-T
Everest Has Strategically Established a Proprietary mRNA Platform Built on Two Core Technologies: Cancer Vaccines and In Vivo CAR-T EVM16 - Personalized tumor Phase Ia IIT ongoing, partial results mRNA vaccines are designed to vaccine presented at AACR 2026 induce Globally Leading Cancer EVM14 - Tum
Slide 20: In Vivo CAR-T: EVM18 Advances into Human Trials; EVM20 at PCC Stage
In Vivo CAR-T: EVM18 Advances into Human Trials Following Preclinical Proof-of-Concept; EVM20 at PCC Stage POC in NHP Percentage of B cells in peripheral blood B cells in Lymph Node and Spleen Control Group CAR Group First Second Third Dose Dose Dose Remaining CD20+ B Cells (%) (Relative to Control
Slide 21: EVM14: Phase I Dose-Escalation Study Progressing as Planned
EVM14: Phase I Dose-Escalation Study Progressing as Planned Study design enables rapid identification of optimal doses for both monotherapy and combination regimens Phase 1 Clinical Development Plan and Progress • Histologically confirmed unresectable, advanced, recurrent or metastatic squamous non-
Slide 22: EVM16: Partial Phase Ia IIT Data Show Dose-Dependent Immunogenicity
EVM16: Partial Phase Ia IIT Data Show Dose-Dependent Immunogenicity and Encouraging Preliminary Efficacy Signals Clinical development plan and • Phase Ia IIT data showed a progress favourable safety and tolerability profile in late-line cancer Phase Ia IIT study patients • EVM16 elicited strong, dos
Slide 23: A2MS Commercial Platform: Maximising Patient Access
“A2MS” Commercial Platform: Maximising Patient Access Through High Productivity and Efficiency Access/Medical/Marketing/Sales Systematic Platform (A2MS) Medical Marketing Sales Access First • Continue to strengthen A2MS infrastructure Systematic platform • Build full life-cycle, Regulatory Early Hos
Slide 24: BD In-Licensing: Targeting 3–5 Blockbuster Assets Annually from 2026 to 2030
BD In-Licensing: Targeting 3–5 Blockbuster Assets Annually from 2026 to 2030 Approval 3–5 and launch blockbuster within 2–3 assets years Peak sales RMB2bn+ reached peak sales within 5–6 per product years Confidence in BD Execution: Proven global BD capabilities and a fast-growing CBC ecosystem 24
Slide 25: Commercial Portfolio and Pipeline Focused on Five Core Therapeutic Areas
Commercial Portfolio and Pipeline Focused on Five Core Therapeutic Areas Therapeutic Stage (China) Product Indication Stage (ex-China) Partner Rights Territories Area Pre-clinical Phase I Phase II Phase III NDA Approval NEFECON® IgAN Approved Approved in US, EU Asahi KASEI Greater China, South Korea
Slide 26: Early-Stage and Late-Stage/Commercial BD Working in Tandem
Early-Stage and Late-Stage/Commercial BD Working in Tandem Sales revenue exceeding First full year of RMB1.4 billion commercialisation NEFECON® EVER001 model model In-licensed + Proprietary assets In-license late-stage assets Internal 02 Strengthen development commercial platform Early-stage BD + La
Slide 27: International Operating Strategy: Co-Commercialising in the U.S. and EU with NovaBridge
International Operating Strategy: Co-Commercialising in the U.S. and EU with NovaBridge While Rapidly Building Commercial Capabilities Across Asia Through M&A EU USA ASIA SEA ➢ Global co-development and co-commercialisation partnership with NovaBridge ➢ EverArc emerging-markets platform anchored in
Slide 28: 2026 Key Milestones
2026 Key Milestones Pipeline Expected milestone Expected timing Approval and launch in Chinese Mainland Q1 2026 EVER001 Out-licensing agreement Q2 2026 BLA submission in Chinese Mainland Q2 2026 VIS-101 Phase IIb clinical trial initiated Q3 2026 Approval and launch in Chinese Mainland Q3 2026 Partic
Slide 29: 2030 Strategic Goal: Surpass RMB15 Billion in Revenue
2030 Strategic Goal: Surpass RMB15 Billion in Revenue and Become a Leading Asia-Based Integrated Innovative Biopharmaceutical Company 2030 Target: Revenue surpassing RMB15 billion Become a leading Asia-based, integrated innovative biopharmaceutical company Cardiovascular / Autoimmune Acute and Nephr
Slide 30: Q&A
Q&A Contact us: IR@everestmedicines.com